Jeremy Chien, Ph.D.

Assistant Professor
Assistant Director, Translational Genomics, The University of Kansas Cancer Center
Department of Cancer Biology

Ph.D., The University of Kansas Medical Center, 2000
Postdoctoral, Mayo Clinic, 2000-2006

My research program focuses on the molecular mechanisms of ovarian carcinogenesis.  Using integrated approaches in genomics, functional genomics, genetics, and molecular biology, I am characterizing genetic and genomic alterations in early-stage ovarian cancer, recurrent disease, and chemotherapy resistant ovarian cancer.  In particular, I have the following programs:

1.       Integrated Functional Genomics and Proteomics to Uncover Novel Mechanisms of Chemotherapy Resistance: Funded by the Department of Defense Ovarian Cancer Academy, this research program focuses on using gene expression microarrays and affinity-based proteomics to identify candidate proteins and biological pathways associated with cisplatin resistance.

2.       Mouse models of tubal carcinogenesis: Funded by the Department of Defense Pilot award, this program focuses on developing mouse models to study the cellular origin of ovarian cancer.

3.       TGF-β Signaling in Ovarian Cancer Metastasis: This program focuses on dissecting the role of serine protease HtrA1 in TGF-β signaling, epithelial-mesenchymal transition, cell-cell and cell-matrix adhesion, and metastasis.

4.       Development of genetic biomarkers for ovarian cancer: This program focuses on developing genome-based technologies and screening modalities for detecting early-stage ovarian cancer.  As an initial step in developing genetic biomarkers, we completed sequencing of early-stage ovarian cancer genomes, and we are currently analyzing the whole genome sequencing data to identify candidate genes associated with the risk of developing ovarian cancer.  In addition, we are analyzing cancer genomes to identify somatic mutations that could be developed as genetic biomarkers for ovarian cancer detection and screening.

Selected Publications

The Cancer Genome Atlas Research Network, (Participants are arranged by area of contribution and then by institution.), Disease working group and tissue source sites, Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, Iacocca M, Imielinski M, Kalloger S, Karlan BY, Levine DA, Mills GB, Morrison C, Mutch D, Olvera N, Orsulic S, Park K, Petrelli N, Rabeno B, Rader JS, Sikic BI, Smith-McCune K, Sood AK, (2011)Integrated genomic analyses of ovarian carcinoma. Nature 474:609-15.

Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, Ota T, Mariani A, Podratz KC, Chien J*, Shridhar V*. (2011)Expression and functional significance of HtrA1 loss in endometrial cancer. Clin Cancer Res. 17:427-36. *Co-corresponding authors

Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB, Chien J. (2011) Minichromosome Maintenance Protein 7 as a Potential Prognostic Factor for Progression-Free Survival in High-Grade Serous Carcinomas of the Ovary. Mod Pathol 24:277-87.

Chien J, Takayo Ota, Giovanni Aletti, Ravi Shridhar, Mariarosaria Boccellino, Lucio Quagliuolo, Alfonso Baldi, and Viji Shridhar. (2009) Serine protease HtrA1 associates with microtubules and inhibits cell migration. Molecular and Cellular Biology 29:4177-87.

Chien J, Jian-Bing Fan, Debra A. Bell, Craig April, Brandy Klotzle, Takayo Ota, Wilma L. Lingle, Jesus Gonzalez Bosquet, Viji Shridhar, and Lynn C. Hartmann. (2009) Analysis of Gene Expression in Stage I Serous Epithelial Ovarian Cancer Identifies Critical Pathways Altered in Ovarian Cancer. Gynecologic Oncology 114:3-11.

Chien J, Xiaoping He, and Viji Shridhar*. (2009) Identification Of Tubulins As Substrates Of Serine Protease HtrA1 By Mixture-Based Oriented Peptide Library Screening. Journal of Cellular Biochemistry 107:253-63

Funmi Ajayi, Nickalus Congosoa, Thomas Gaffey, William Watson, Alfonso Baldi, Peeyush Lala, Viji Shridhar, Brian Brost, and Chien J. (2008) Elevated expression of HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. Am J Obstetrics & Gynecology 199:557.e1-10.

Chien J, Keishi Narita, Ramandeep Rattan, Shailendra Giri, Ravi Shridhar, Julie Staub, Daniah Beleford, Jinping Lai, Julian Molina, Scott H. Kaufmann, George C. Prendergast, and Viji Shridhar. (2008) Candidate tumor suppressor gene TCEAL7 negatively regulates c-Myc. Oncogene 27:7223-34.

Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. (2006) Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 116:1994-2004.

Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, Smith DI, and Shridhar V. (2005) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24:5089-100.

Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH, Shridhar V. (2004) A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 23:1636-44.

Chien J, Ren Y, Qing Wang Y, Bordelon W, Thompson E, Davis R, Rayford W, Shah G. (2001) Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Molecular Cell Endocrinology 181:69-79.

Chien, J, and Shah GV. (2001)  Role of stimulatory guanine nucleotide binding protein (Gsα) in proliferation of PC-3M prostate cancer cells. International Journal of Cancer 91:46-54.

Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG, and Shah GV. (1999) Constitutive activation of stimulatory guanine nucleotide binding protein (GsαQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 18:3376-82.

Last modified: Jun 29, 2017


Jeremy Chien, Ph.D.
Assistant Professor
Assistant Director, Translational Genomics, The University of Kansas Cancer Center